Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
Prostate Cancer
9 articles
Dual Checkpoint Inhibition Shows Promise in Molecularly Selected Prostate Cancer Patients
Phase II trial reveals promising results for dual immune checkpoint inhibition in specific mCRPC patients.
ADT and Heart Failure: New Study Reveals Increased Risk for Prostate Cancer Patients
Meta-analysis finds androgen deprivation therapy linked to higher heart failure risk in prostate cancer patients.
Novel Neoadjuvant Chemoradiation Approach Shows Promise for High-Risk Prostate Cancer
Study evaluates docetaxel plus radiotherapy before surgery in high-risk prostate cancer patients
Cabazitaxel: A Promising Second-Line Treatment for Advanced Prostate Cancer
Meta-analysis shows cabazitaxel improves survival in metastatic castration-resistant prostate cancer patients.
PARP Inhibitor Shows Promise in Delaying Prostate Cancer Progression
Study explores rucaparib as ADT-sparing option for nonmetastatic prostate cancer with DNA repair defects
Prostate Cancer Immunotherapy Combo Falls Short in Phase 2 Trial
AZD4635 with durvalumab or oleclumab shows limited efficacy in metastatic castration-resistant prostate cancer
Enzalutamide Improves Outcomes in High-Risk Prostate Cancer
Enzalutamide plus leuprolide or alone significantly delays metastasis in high-risk prostate cancer
Oral Relugolix: A New Horizon in Prostate Cancer Treatment
Study shows oral relugolix has similar quality of life impact to leuprolide for prostate cancer patients
Identifying High-Risk Prostate Cancer Patients for Treatment Escalation
Study finds factors predicting early PSA failure in prostate cancer, suggesting need for more aggressive treatment